Abstract
Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative diseases that carry intrinsically the potential for leukemic transformation. The aims of this study were (1) to detect involvement of N-and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU). Samples of PV and ET patients were analyzed with a polymerase chain reaction. No N-or K-ras mutations were detected. A positive score for MSI in chromosome 7 was found in 1 patient with PV during leukemic transformation. Three of 69 patients developed acute myelogenous leukemia, 2 with PV and 1 with ET. As of this report, the overall incidence of leukemic transformation is 5.7% (2/35 patients) in PV and 3.3% (1/30 patients) in ET patients treated with HU. These results indicate that (1) MSI is a genetic marker that can be detected, even in a small group of patients, at the blastic phase of the disease and (2) no increased leukemogenicity was noted in this group of patients treated with HU.
Similar content being viewed by others
References
Vardiman JW. Chronic myelogenous leukemia and the myelopro-liferative disorders. In: Knowles DM, ed.Neoplastic Hematopathology. Baltimore, Md: Williams and Wilkins; 1992:1405–1438.
Hoffman R, Silverstein MN, Hromas R. Primary thrombocythemia. In: Hoffman R, Benz EZ Jr, Shattil SJ, Furie B, Cohen HJ, Silbersten LE, eds.Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 1995:1174–1184.
Raskid WH, Jacobson R, Murphy S, Adamson JW, Fialkow PJ. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia.J Clin Invest. 1985;75: 1388–1399.
Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications.Blood. 1999;93:417–424.
El-Kasar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets.Blood. 1997;89:128–134.
Belucci S, Janvier M, Tobelen G, et al. Essential thrombocythemias: clinical evolutionary and biological data.Cancer. 1986; 58: 2440–2447.
Cervantens F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.Acta Hematol. 1991;85:124–127.
Landaw SA. Acute leukemia in polycythemia vera.Semin Hematol. 1986;23:156–165.
Najean Y, Deschamps A, Dresch C, Daniel MT, Rain JD, Arrago JP. Acute leukemia and myelodysplasia in polycythemia vera: a clinical study with long-term follow up.Cancer. 1988;61:89–95.
Sessarego M, Deferrari R, Dejana AM, et al. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation: a 12-year study.Cancer Genet Cytogenet. 1989;43:57–65.
Gaidano G, Guerrasio A, Serra A, et al. Mutations in the p53 and Ras family genes are associated with tumor progression of bcr/abl negative chronic myeloproliferative disorders.Leukemia. 1993;7: 946–953.
Gaidano G, Pastore C, Santini Y, et al. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia.Genes Chromosomes Cancer. 1997;19:250–255.
Miller SA, Dyhes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells.Nucleic Acid Res. 1988;16:1215.
Jacobson D, Mills M. A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia.Oncogene. 1994;9:553–563.
Collins S. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.Blood. 1987;70:1233–1244.
Fossum B, Olsen AC, Thorsby E, Gaudernack G. CD8+ cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation.Cancer Immunol Immunother. 1995;40:165–172.
Liang H, Fairman J, Claxton D, Nowell P, Green E, Nagarajan L. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci.Proc Natl Acad Sci U S A. 1998;95:3781–3785.
Horrigan S, Westbrook C, Kim A, Banerjee M, Stock W, Larson R. Polymerase chain reaction-based diagnosis of del(5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.Blood. 1996;88:2665–2670.
Neri A, Fracchiolla NS, Radaelli F, et al. p53 tumour suppressor gene and Ras oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia.Br J Haematol. 1996;93:670–673.
Neuman W, Rubin C, Rachel R, et al. Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders.Blood. 1992;79:1501–1510.
LeBeau M, Espinosa R, Davis E, Eisenbart J, Larson R, Green E. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid disorders.Blood. 1996; 88:1930–1935.
Bilgrami S, Greenberg BR. Polycythemia rubra vera.Semin Oncol. 1995;22:307–326.
Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.Eur J Haematol. 1994;52:134–139.
Nand S, Messmore H, Fisher SG, Bird ML, Schultz W, Fisher RI. Leukemic transformation of PV: analysis of risk factors.Am J Hematol. 1990;34:32–36.
West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20 year period.South Med J. 1987;80:323–327.
Sharon R. Treatment of polycythemia vera with hydroxyurea.Cancer. 1986;57:718–720.
Nand S, Stock W, Godwin J, Fisher S. Leukemogenic risk of hydrox-yurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis.Am J Hematol. 1996; 52:42–46.
Furgerson JL, Vukelja SJ, Baker WS, O’Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.Am J Hematol. 1996;51: 137–140.
Pulik M, Lionnet F, Genet P, Petitdidier C, Jary L, Tuahri T. Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea.Am J Hematol. 1996;53:207–208.
Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulfan and hydroxyurea: long-term follow-up in a randomized clinical trial.Br J Haematol. 2000;110:577–583.
Sterkers Y, Preudhomme C, Lai JL, et al. acute myeloid leukemia and myelodysplastic syndromes following essential thrombo-cythemia treated with hydroxyurea: high proportion of cases with 17p deletion.Blood. 1998;91:616–622.
Author information
Authors and Affiliations
About this article
Cite this article
Mavrogianni, D., Viniou, N., Michali, E. et al. Leukemogenic Risk of Hydroxyurea Therapy as a Single Agent in Polycythemia Vera and Essential Thrombocythemia: N-and K-ras Mutations and Microsatellite Instability in Chromosomes 5 and 7 in 69 Patients. Int J Hematol 75, 394–400 (2002). https://doi.org/10.1007/BF02982131
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02982131